NMN (Nicotinamide Mononucleotide)

What is NMN?

NMN (nicotinamide mononucleotide) is a naturally occurring molecule — your body produces it as an intermediate step in NAD+ synthesis, and it’s also present in small amounts in foods like edamame, broccoli, avocado, and beef. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in hundreds of cellular reactions, particularly energy metabolism and DNA repair, and its levels decline measurably with age — which is the core rationale behind NMN supplementation.

NMN sits one enzymatic step closer to NAD+ than NR (nicotinamide riboside) — NMN is converted to NAD+ directly by NMNAT enzymes, while NR must first be converted to NMN (via NRK enzymes) before that same final step. This “one fewer step” framing is the most commonly cited theoretical argument for NMN over NR, though it hasn’t been validated by head-to-head human trials measuring the outcomes that actually matter.

Human trial data for NMN has grown substantially since 2019, including studies showing improvements in blood NAD+ levels, physical performance measures, and muscle insulin sensitivity in specific populations. NMN’s regulatory history has been unusually turbulent for a supplement — the FDA’s 2022 determination that NMN couldn’t be marketed as a dietary supplement (because a company had filed for its investigation as a new drug) caused significant disruption, before the FDA reversed that position in 2023.

NMN is almost always discussed alongside NR as the two leading oral NAD+ precursors, and alongside direct NAD+ supplementation (including IV NAD+) as alternative routes to the same underlying goal of raising cellular NAD+ availability.

How it works

NMN → NAD+ Biosynthesis Pathway

NMN is converted to NAD+ by a family of enzymes called NMNATs (nicotinamide mononucleotide adenylyltransferases), found in the nucleus, cytoplasm, and mitochondria. This is the final step of what’s called the “salvage pathway” — the body’s primary route for recycling NAD+ from its breakdown products, as opposed to synthesizing it from scratch from dietary tryptophan (the de novo pathway). Because the salvage pathway is the dominant source of NAD+ in most tissues, supplying more of its substrates — like NMN — is the rationale for raising NAD+ levels through supplementation.

The SLC12A8 Transporter

For years, it was unclear how NMN — a relatively large, charged molecule — could be taken up directly by cells, leading some researchers to argue NMN must first be broken down to NR before absorption. The 2019 discovery of SLC12A8, a dedicated NMN transporter expressed in the small intestine and other tissues, provided a direct uptake mechanism for NMN itself. This finding was significant for the NMN-vs-NR debate, as it supports the idea that NMN can be absorbed and utilized without first being converted to NR — though the relative contribution of direct NMN transport versus conversion routes in humans is still being clarified.

NAD+ → Sirtuin/PARP/CD38 Effects

Once converted to NAD+, the downstream effects are shared across all NAD+ precursors regardless of route. NAD+ is a required cofactor for sirtuins (a family of proteins involved in cellular stress response and implicated in lifespan regulation in animal models), PARPs (involved in DNA damage repair), and CD38 (an enzyme that consumes NAD+ and increases with age, partly driving the age-related NAD+ decline). Restoring NAD+ levels is thought to support all three of these pathways — more substrate available for sirtuin and PARP activity, even as CD38 continues to consume NAD+ at an age-elevated rate.

What the research shows

What the community reports

NMN is one of the most widely used supplements in the longevity community, often as the entry point into NAD+-focused stacking, frequently alongside other compounds discussed by figures like David Sinclair.

Common misconceptions